The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217)
- 14 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 21 (2), 170-174
- https://doi.org/10.1016/j.clcc.2021.09.005
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Bildung und Forschung (01KG1817)
This publication has 18 references indexed in Scilit:
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC StudyJournal of Clinical Oncology, 2015
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerScience Translational Medicine, 2015
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic FeaturesJournal of Clinical Oncology, 2011
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon CancerJournal of Clinical Oncology, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised studyThe Lancet, 2007
- Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition StagingJNCI Journal of the National Cancer Institute, 2004
- Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site GroupJournal of Clinical Oncology, 2004
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancerThe Lancet, 1995